Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

G1 Therapeutics Inc (GTHX)

G1 Therapeutics Inc (GTHX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

G1 Therapeutics Inc 700 Park Offices Drive Suite 200 Research Triangle Park NC 27709 USA

www.g1therapeutics.com P: 919-213-9835 F: 919-741-5830

Description:

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC.

Key Statistics

Overview:

Market Capitalization, $K 208,414
Enterprise Value, $K 227,694
Shares Outstanding, K 52,234
Annual Sales, $ 82,510 K
Annual Net Income, $ -47,970 K
Last Quarter Sales, $ 14,870 K
Last Quarter Net Income, $ -10,880 K
EBIT, $ -39,530 K
EBITDA, $ -37,540 K
60-Month Beta 1.73
% of Insider Shareholders 8.23%
% of Institutional Shareholders 24.21%
Float, K 47,935
% Float 91.77%
Short Volume Ratio 0.41

Growth:

1-Year Return 62.20%
3-Year Return -81.06%
5-Year Return -81.54%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 63.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.21 on 02/28/24
Latest Earnings Date 05/01/24 [BMO]
Earnings Per Share ttm -0.95
EPS Growth vs. Prev Qtr 40.00%
EPS Growth vs. Prev Year 71.23%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

GTHX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -106.04%
Return-on-Assets % -33.99%
Profit Margin % -58.14%
Debt/Equity 1.46
Price/Sales 2.44
Price/Cash Flow N/A
Price/Book 5.66
Book Value/Share 0.68
Interest Coverage -3.47
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar